Galera Therapeutics (GRTX) Competitors $0.02 0.00 (-2.78%) As of 02:40 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesOptions ChainSEC FilingsShort InterestTrendsBuy This Stock GRTX vs. EVAX, CLDI, CNSP, GLTO, XBIO, GRI, ONCO, NKGN, SNGX, and APVOShould you be buying Galera Therapeutics stock or one of its competitors? The main competitors of Galera Therapeutics include Evaxion A/S (EVAX), Calidi Biotherapeutics (CLDI), CNS Pharmaceuticals (CNSP), Galecto (GLTO), Xenetic Biosciences (XBIO), GRI Bio (GRI), Onconetix (ONCO), NKGen Biotech (NKGN), Soligenix (SNGX), and Aptevo Therapeutics (APVO). These companies are all part of the "pharmaceutical products" industry. Galera Therapeutics vs. Its Competitors Evaxion A/S Calidi Biotherapeutics CNS Pharmaceuticals Galecto Xenetic Biosciences GRI Bio Onconetix NKGen Biotech Soligenix Aptevo Therapeutics Evaxion A/S (NASDAQ:EVAX) and Galera Therapeutics (NASDAQ:GRTX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, dividends, profitability, valuation, analyst recommendations, media sentiment, institutional ownership and earnings. Do institutionals and insiders hold more shares of EVAX or GRTX? 11.0% of Evaxion A/S shares are owned by institutional investors. Comparatively, 50.8% of Galera Therapeutics shares are owned by institutional investors. 41.6% of Evaxion A/S shares are owned by insiders. Comparatively, 12.9% of Galera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Do analysts prefer EVAX or GRTX? Evaxion A/S presently has a consensus target price of $11.00, suggesting a potential upside of 86.44%. Given Evaxion A/S's stronger consensus rating and higher probable upside, equities research analysts plainly believe Evaxion A/S is more favorable than Galera Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Evaxion A/S 1 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.33Galera Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Does the media favor EVAX or GRTX? In the previous week, Evaxion A/S had 4 more articles in the media than Galera Therapeutics. MarketBeat recorded 4 mentions for Evaxion A/S and 0 mentions for Galera Therapeutics. Evaxion A/S's average media sentiment score of 0.16 beat Galera Therapeutics' score of 0.00 indicating that Evaxion A/S is being referred to more favorably in the media. Company Overall Sentiment Evaxion A/S Neutral Galera Therapeutics Neutral Is EVAX or GRTX more profitable? Galera Therapeutics' return on equity of 0.00% beat Evaxion A/S's return on equity.Company Net Margins Return on Equity Return on Assets Evaxion A/SN/A -319.52% -63.56% Galera Therapeutics N/A N/A -99.34% Which has higher earnings and valuation, EVAX or GRTX? Evaxion A/S has higher revenue and earnings than Galera Therapeutics. Evaxion A/S is trading at a lower price-to-earnings ratio than Galera Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEvaxion A/S$3.18M2.61-$10.57M-$1.32-4.47Galera TherapeuticsN/AN/A-$59.08M-$0.19-0.09 Which has more volatility and risk, EVAX or GRTX? Evaxion A/S has a beta of 0.23, indicating that its stock price is 77% less volatile than the S&P 500. Comparatively, Galera Therapeutics has a beta of 1.98, indicating that its stock price is 98% more volatile than the S&P 500. SummaryEvaxion A/S beats Galera Therapeutics on 9 of the 14 factors compared between the two stocks. Get Galera Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for GRTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding GRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart GRTX vs. The Competition Export to ExcelMetricGalera TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.32M$1.03B$6.01B$10.23BDividend YieldN/A4.84%5.66%4.70%P/E Ratio-0.051.3085.3526.57Price / SalesN/A30.60584.94179.70Price / CashN/A17.6438.3262.20Price / Book-0.017.3112.726.53Net Income-$59.08M-$7.96M$3.30B$275.96M7 Day PerformanceN/A30.42%1.05%-1.40%1 Month PerformanceN/A27.56%7.56%5.16%1 Year PerformanceN/A-6.52%79.69%31.55% Galera Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)GRTXGalera TherapeuticsN/A$0.02-2.8%N/A-75.7%$1.32MN/A-0.0530Gap UpEVAXEvaxion A/S2.2721 of 5 stars$3.76-1.1%$11.00+192.6%-52.0%$5.33M$3.34M-2.8560CLDICalidi BiotherapeuticsN/A$1.52-1.3%N/AN/A$5.21MN/A0.0038CNSPCNS Pharmaceuticals2.5258 of 5 stars$9.00+1.2%$20.00+122.2%-86.3%$5.11MN/A0.005Positive NewsAnalyst ForecastGLTOGalecto0.5902 of 5 stars$3.72-2.1%$10.00+168.8%+106.0%$5.03MN/A-0.2840News CoverageGap DownXBIOXenetic Biosciences0.7602 of 5 stars$3.13-3.4%N/A+133.6%$5.00M$2.45M-1.574News CoverageAnalyst ForecastGap DownTrading HaltedGRIGRI Bio2.4928 of 5 stars$2.06+4.0%$22.50+992.2%-73.1%$4.98MN/A-0.181Analyst ForecastONCOOnconetix1.1366 of 5 stars$3.11-3.1%N/A-99.0%$4.96M$2.52M0.0012Analyst ForecastNKGNNKGen Biotech0.13 of 5 stars$0.11flatN/A-99.7%$4.94MN/A-0.02N/ANews CoverageSNGXSoligenix3.1074 of 5 stars$1.16+4.5%$6.00+417.2%-55.4%$4.76M$120K-0.3120Analyst ForecastAPVOAptevo Therapeutics1.479 of 5 stars$1.45+0.7%N/A-100.0%$4.73M$3.11M0.0050Analyst ForecastGap Down Related Companies and Tools Related Companies EVAX Competitors CLDI Competitors CNSP Competitors GLTO Competitors XBIO Competitors GRI Competitors ONCO Competitors NKGN Competitors SNGX Competitors APVO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:GRTX) was last updated on 10/10/2025 by MarketBeat.com Staff From Our PartnersBitcoin grabs headlines, but smart money likes this tokenIf you're a futures trader (or want to be one), this could be the biggest shift you'll ever see in the prop fi...Neuro Street Trading Academy | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | Sponsored"I'm risking my reputation on this"If I'm right about what's coming, this could be the most important book you'll read this yearCrypto 101 Media | Sponsored1 Hour Once A DayMy top income trading expert, Dave Aquino, just released a 1-hour trading strategy designed specifically to he...Base Camp Trading | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMiss This IRS Strategy Now, Regret It LaterWith Donald Trump back in the White House, many believe an economic revival could be underway — but it also br...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Galera Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Galera Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
